secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001171843-26-003052
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q1 ORLADEYO rev $148.3M (+11% YoY); non-GAAP op profit $54.2M; licenses EU navenibart rights for $70M upfront
--------------------------------------------------------------------------------

- ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.
- Non-GAAP operating profit of $54.2M; guidance reaffirmed: FY2026 ORLADEYO rev $625-645M, total rev $635-660M, op ex $450-470M.
- Licensed European navenibart rights to Neopharmed Gentili for $70M upfront, up to $275M milestones, plus 18-30% royalties.
- Navenibart pivotal study ALPHA-ORBIT enrollment on track to complete by June 2026; US regulatory filing targeted by end 2027.
- Appointed Sandeep Menon as Chief R&D Officer in April; ended avoralstat DME program to focus on rare diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/f8k_050626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer